Thinning revenues: inside the $14bn Eliquis patent cliff - Pharmaceutical Technology

With $14.2bn in projected revenue losses over six years, the Eliquis LOE event is set to become one of the most consequential patent cliffs in pharmaceutical history. With $14.2bn in projected revenue losses over six years, the Eliquis loss-of-exclusivity event is set to become one of the most consequential patent cliffs in pharmaceutical history — and a stark illustration of how quickly generic entry can dismantle even the industry's most entrenched brands. With global sales of $14.4bn in 2025, the Bristol Myers Squibb (BMS)- and Pfizer-partnered anticoagulant ranks among the industry’s highest-grossing small molecules. Credit: Jonathan Weiss / Shutterstock.com. Eliquis…

Source: Pharmaceutical Technology